Literature DB >> 12404669

Tolerability and safety aspects of mirtazapine.

David J Nutt1.   

Abstract

The tolerability and safety profile of the noradrenergic and specific serotonergic antidepressant (NaSSA) mirtazapine reflects its unique pharmacological profile. The 5-HT(2) blocking effect contributes towards its anxiolytic effects and benefits on sleep, as well as preventing the sexual dysfunction that may occur with non-specific stimulation of the serotonin system by drugs such as the selective serotonin reuptake inhibitors (SSRIs). In addition, 5-HT(3) blockade by mirtazapine helps to prevent nausea and vomiting. Weight gain is the most commonly reported side-effect of mirtazapine, although there is evidence to suggest that this is not a significant problem during long-term treatment. In conclusion, mirtazapine has a good tolerability and safety profile that demonstrates several benefits over other antidepressants. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12404669     DOI: 10.1002/hup.388

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  12 in total

1.  Panic Attacks During Escalation of Mirtazapine.

Authors:  Timothy R. Berigan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-04

2.  Mirtazapine to reduce methamphetamine use: a randomized controlled trial.

Authors:  Grant N Colfax; Glenn-Milo Santos; Moupali Das; Deirdre McDermott Santos; Tim Matheson; James Gasper; Steve Shoptaw; Eric Vittinghoff
Journal:  Arch Gen Psychiatry       Date:  2011-11

Review 3.  Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine.

Authors:  Yvan Jamilloux; Sébastien Kerever; Tristan Ferry; Christiane Broussolle; Jérôme Honnorat; Pascal Sève
Journal:  Clin Drug Investig       Date:  2016-10       Impact factor: 2.859

Review 4.  A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy.

Authors:  J Michael Bostwick
Journal:  Mayo Clin Proc       Date:  2010-04-29       Impact factor: 7.616

5.  Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.

Authors:  Marcio Versiani; Ricardo Moreno; Catharina J A Ramakers-van Moorsel; Albert J Schutte
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

6.  A Review of the Literature of Mirtazapine in Co-Occurring Depression and an Alcohol Use Disorder.

Authors:  J R Cornelius; T A Chung; A B Douaihy; L Kirisci; J Glance; J Kmiec; M A Wesesky; D FitzGerald; I Salloum
Journal:  J Addict Behav Ther Rehabil       Date:  2016-12-30

7.  Identifying predictive clinical characteristics of the treatment efficacy of mirtazapine monotherapy for major depressive disorder.

Authors:  Takahiro Tsutsumi; Hiroko Sugawara; Ryoko Ito; Mizuho Asano; Satoru Shimizu; Jun Ishigooka; Katsuji Nishimura
Journal:  Neuropsychiatr Dis Treat       Date:  2016-10-05       Impact factor: 2.570

8.  'Doing the right thing': factors influencing GP prescribing of antidepressants and prescribed doses.

Authors:  Chris F Johnson; Brian Williams; Stephen A MacGillivray; Nadine J Dougall; Margaret Maxwell
Journal:  BMC Fam Pract       Date:  2017-06-17       Impact factor: 2.497

Review 9.  Choosing an antidepressant.

Authors:  Philip Boyce; Cassandra Ma
Journal:  Aust Prescr       Date:  2021-02-01

10.  Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial.

Authors:  Phillip O Coffin; Glenn-Milo Santos; Jaclyn Hern; Eric Vittinghoff; John E Walker; Tim Matheson; Deirdre Santos; Grant Colfax; Steven L Batki
Journal:  JAMA Psychiatry       Date:  2020-03-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.